NUTM1 and cancer: Given the great success in drugs targeting cancer-driven fusion proteins such as Gleevec (targeting BCR-ABL in chronic myeloid leukemia) [63,64], directly targeting the NUTM1 fusion proteins themselves is another promising avenue for targeted therapy.